Abstract
Introduction In aortic root surgery, Valve Sparing Aortic Root Replacement (VSARR) is an attractive alternative by mitigating the risks inherent to prosthetic valves, however little is known about the variables that impact its performance and durability. We have reviewed our mid to long-term outcomes following VSARR and describe factors that impact patient survival and aortic valve reintervention and insufficiency.
Methods A retrospective review of 284 consecutive patients undergoing VSARR between November 1999 and January 2022 at Austin Health, Melbourne, Australia, was undertaken, with median follow up of 6.43 ± 4.83 years, but up to 22.0 years.
Results The median age at intervention was 60.0 years (IQR 48.0-67.0), of which 68 (23.9%) had bicuspid aortic valve (BAV) disease, 27 (9.5%) Marfan’s disease, 119 (41.9%) severe aortic root dilation (>50mm), and 155 (54.6%) severe aortic insufficiency at the time of intervention. The 30-day mortality was 1.8%, with freedom from mortality of 96.0% (95% CI 92.6-97.8%) at 5 years, 88.2% (95% CI 81.4-92.6%) at 10 years and 78.6% (66.2-86.9%) at 15 years. Freedom from aortic re-intervention was 92.2% (95% CI 87.7-95.2%) at 5 years, 79.8% (95% CI 71.8-85.8%) at 10 years, and 74.1% (63.5-82.0%) at 15 years. Predictors of re-intervention were concomitant leaflet repair (HR 8.13, 95%CI 1.07-61.7) and bicuspid valvulopathy (HR 2.23, 95% CI 1.07-4.68). The freedom from aortic insufficiency was 89.1% (95% CI 83.5-92.9%), 84.9% (95% CI 77.8-89.9%) and 80.7% (71.0-87.4%) at 5-, 10- and 15-years respectively.
Conclusion VSARR has excellent long-term outcomes, with low mortality and re-intervention rates. Concomitant Leaflet repair and Bicuspid Aortopathy are the only long-term predictors of re-intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Varun Sharma is a recipient of the National Heart Foundation of Australia PhD Scholarship
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Health and Research Ethics Committees (HREC) of Austin Health, Melbourne, Victoria to meet ethical and legal requirements, and individual consent was waived (HREC LNR/17/Austin/82).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Can provide data at request
